Please ensure Javascript is enabled for purposes of website accessibility

Why Intercept Pharmaceuticals Stock Is Crashing Today

By George Budwell – Updated Jun 29, 2020 at 10:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares are taking a step back after the FDA rejected the company's NASH candidate.

What happened

Intercept Pharmaceuticals (ICPT -0.85%) is starting the week on a sour note. The drugmaker's shares dropped by as much as 38% in pre-market trading Monday morning in response to the Food and Drug Administration's decision to reject obeticholic acid (OCA) as a treatment for liver fibrosis stemming from nonalcoholic steatohepatitis (NASH).

The FDA's denial reportedly centered around OCA's predicted clinical benefit relative to its potential risks. The agency apparently wanted a well-defined (and highly favorable) risk-to-reward ratio in order to approve the drug on an accelerated basis. As of 9:57 a.m. EDT on Monday, the biotech's shares were still down by a whopping 37.9% in the wake of this disappointing regulatory outcome.

A human liver illustrating the difference between a healthy liver and a fibrotic one.

Image source: Getty Images.

So what

Intercept was set to become the first company with an FDA-approved NASH medication. That's a big deal because the first NASH drug to hit the market could generate anywhere from $2 billion to $5 billion in annual sales within the first five years after approval.     

Now what

The good news is that the agency did recommend that Intercept submit additional efficacy and safety data from OCA's ongoing Regenerate study. What's more, the FDA said that the long-term outcomes phase of the study should continue as well. So there's a chance that OCA could still win this high-value indication at some point down the road.

The bad news is that there are scores of other biotechs racing to bring a NASH treatment to market. Therefore, Intercept will definitely need some luck in order to maintain its potential first-mover advantage after this regulatory setback. 

George Budwell owns shares of Intercept Pharmaceuticals. The Motley Fool recommends Intercept Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intercept Pharmaceuticals Stock Quote
Intercept Pharmaceuticals
$13.94 (-0.85%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.